Zepatier (Elbasvir/Grazoprevir)

Save 35% on Zepatier from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer of Zepatier for Europe: Organon Heist bv Industriepark 30 2220 Heist-op-den-Berg Belgium

Zepatier is a combination medicine (elbasvir and grazoprevir) that acts as an antiviral medicine to treat long-term hepatitis C.  Zepatier is used taken by adults only.  Zepatier works by blocking 2 protieins required by the hepatitis C virus.  In this way Zepatier prevents the virus from growing and reproducing.  Zepatier removes the infection permanently.  Zepatier is taken alone or in combination with other medicines including ribavirin.

Information about Zepatier (Elbasvir/Grazoprevir)

Zepatier is a combination antiviral medication containing Elbasvir (a protease inhibitor) and Grazoprevir (an NS5A inhibitor), both of which work together to treat Hepatitis C virus (HCV) infection. This medication targets different stages of the viral replication process, inhibiting the virus's ability to multiply and spread in the body. Zepatier is used to help clear HCV from the bloodstream and is often used in combination with other treatments, depending on the specific genotype of the virus.

Product Highlights

• Zepatier is indicated for the treatment of chronic HCV in adults with genotypes 1 and 4 of the virus.
• It is also used in both treatment-naive and treatment-experienced patients.
• In some cases, Zepatier may be prescribed for people with HCV-related cirrhosis and those co-infected with HIV.

Key Ingredient

• Elbasvir
• Grazoprevir

Key Benefits

• Zepatier has shown to significantly improve the chances of eradicating the Hepatitis C virus, with high rates of sustained virologic response (SVR) following treatment.
• Zepatier is taken as a single pill once daily, making it easier for patients to adhere to the treatment regimen.
• Zepatier is effective against genotypes 1 and 4 of Hepatitis C, which are common in many parts of the world.
• Many patients tolerate Zepatier well, with few side effects compared to older HCV treatments.

Direction of Use

• Zepatier is taken as a single tablet once a day, with or without food.
• The typical treatment duration is 12 weeks, but this may vary depending on the patient's genotype, cirrhosis status, and previous treatment history.
• The healthcare provider will determine the exact dosing schedule. 

Safety Concerns

• Liver function tests should be monitored during treatment, particularly in patients with pre-existing liver disease (such as cirrhosis).
• In patients co-infected with Hepatitis B, there is a risk of Hepatitis B reactivation during or after treatment with Zepatier. This requires close monitoring.
• Zepatier may interact with other medications, especially those that affect the liver’s cytochrome P450 system. It is crucial to inform the healthcare provider about all medications, including over-the-counter drugs and supplements.
• While Zepatier is generally well-tolerated, side effects may include fatigue, headache, nausea, and liver enzyme elevations. Rarely, more serious side effects such as allergic reactions or liver damage may occur.

Avoid Zepatier (Elbasvir/Grazoprevir) If

• You are allergic to Elbasvir, Grazoprevir, or any other component of Zepatier.
• You have a severe liver disease, including advanced cirrhosis, or if you have liver failure.
• You are taking rifampin (an antibiotic) or carbamazepine (a seizure medication), as these can significantly reduce the effectiveness of Zepatier.
• You are pregnant or planning to become pregnant, as the safety of Zepatier during pregnancy has not been established, and the treatment may have risks for the unborn child.
• You are breastfeeding, as it is not known if Zepatier passes into breast milk.